{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+cell+infusion&page=2", "query": { "intervention": "B cell infusion", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+cell+infusion&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T12:02:48.037Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00602693", "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma", "Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "umbilical cord blood transplantation", "type": "BIOLOGICAL" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Treg infusion", "type": "BIOLOGICAL" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2007-07-23", "completion_date": "2015-04-16", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602693" }, { "nct_id": "NCT00612716", "title": "Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Stem cell infusion", "type": "BIOLOGICAL" }, { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 6, "start_date": "1999-10-06", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612716" }, { "nct_id": "NCT04881240", "title": "Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia, Refractory", "Pediatric ALL" ], "interventions": [ { "name": "CD19-CAR(Mem) T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 60, "start_date": "2024-02-14", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881240" }, { "nct_id": "NCT00802113", "title": "Autologous and Allogeneic Transplant for Relapsed Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkins Disease" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 30, "start_date": "2003-06", "completion_date": "2014-10-22", "has_results": true, "last_update_posted_date": "2019-03-27", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 6, "location_summary": "Chicago, Illinois • Hackensack, New Jersey • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00802113" }, { "nct_id": "NCT02366143", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1202, "start_date": "2015-03-31", "completion_date": "2020-12-07", "has_results": true, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 61, "location_summary": "Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02366143" }, { "nct_id": "NCT00006368", "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Neoplastic Syndrome" ], "interventions": [ { "name": "yttrium Y 90-edotreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-01", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006368" }, { "nct_id": "NCT02982915", "title": "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aging Frailty" ], "interventions": [ { "name": "Longeveron Mesenchymal Stem Cells (LMSCs)", "type": "BIOLOGICAL" }, { "name": "Fluzone High Dose Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Longeveron Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "65 Years to 90 Years" }, "enrollment_count": 62, "start_date": "2016-11", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 6, "location_summary": "Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982915" }, { "nct_id": "NCT06918990", "title": "Treatment of Antibody-Mediated Rejection (ABMR) With CarBel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "Carfilzomib", "type": "BIOLOGICAL" }, { "name": "Belatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 25, "start_date": "2026-05-27", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06918990" }, { "nct_id": "NCT04992780", "title": "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer Stage" ], "interventions": [ { "name": "Hypo-Fractionation", "type": "RADIATION" }, { "name": "Standard-Fractionation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-02-25", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2023-12-07", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 6, "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Topeka, Kansas + 3 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lee's Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04992780" }, { "nct_id": "NCT03548207", "title": "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "JNJ-68284528", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2018-06-29", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-09-28T12:02:48.037Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Duarte, California • San Francisco, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548207" } ] }